--- title: "Senestech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 493 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/286351031.md" datetime: "2026-05-14T03:25:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286351031.md) - [en](https://longbridge.com/en/news/286351031.md) - [zh-HK](https://longbridge.com/zh-HK/news/286351031.md) --- # Senestech | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 493 K Revenue: As of FY2026 Q1, the actual value is USD 493 K, missing the estimate of USD 632 K. EPS: As of FY2026 Q1, the actual value is USD -0.39, missing the estimate of USD -0.33. EBIT: As of FY2026 Q1, the actual value is USD -2.175 M. #### Segment Revenue SenesTech, Inc. operates in a single segment focused on fertility control products for pest management. Total net revenues for the three months ended March 31, 2026, were $493 thousand, an increase of 2% from $485 thousand for the same period in 2025. - **Evolve Product Line**: Revenue from the Evolve product line (Evolve Rat and Evolve Mouse) was $418 thousand in Q1 2026, representing 85% of total revenues, up from $384 thousand (79% of total revenues) in Q1 2025. The increase in Evolve revenues was driven by sales across e-commerce, pest management professionals, and retail channels. - **ContraPest Product Line**: Revenue from ContraPest was $75 thousand in Q1 2026, representing 15% of total revenues, a decline from $101 thousand (21% of total revenues) in Q1 2025. This decline was expected and partially offset the increase in Evolve revenues. #### Operational Metrics - **Gross Profit**: Gross profit for Q1 2026 was $338 thousand (68.6% margin), compared to $313 thousand (64.5% margin) in Q1 2025, reflecting an 8% increase. This improvement was attributed to enhanced production efficiency and average selling prices. Cost of sales was $155 thousand (31.4% of net sales) in Q1 2026, down from $172 thousand (35.5% of net sales) in Q1 2025. - **Research and Development (R&D) Expenses**: R&D expenses increased by 1% to $422 thousand in Q1 2026 from $418 thousand in Q1 2025. This slight increase was primarily due to higher facility-related expenses following a move to a new manufacturing site in April 2025, largely offset by cost-containment efforts. - **Selling, General and Administrative (SG&A) Expenses**: SG&A expenses rose by 31% to $2,035 thousand in Q1 2026 from $1,558 thousand in Q1 2025. This increase was mainly driven by higher professional fees, including $213 thousand in legal expenses for a litigation settlement and increased general corporate activity, as well as higher consulting costs for marketing. Personnel-related costs also included $230 thousand of severance expense and executive search fees. - **Loss from Operations**: The company reported a loss from operations of - $2,119 thousand in Q1 2026, compared to - $1,663 thousand in Q1 2025, representing a 27% increase in loss. - **Interest Income (Expense), Net**: Net interest income was $56 thousand in Q1 2026, a significant increase from net interest expense of - $2 thousand in Q1 2025, primarily due to a higher average balance of cash, cash equivalents, and investments. - **Net Loss**: Net loss for Q1 2026 was - $2,063 thousand, compared to - $1,665 thousand in Q1 2025, an increase of 24%. #### Cash Flow - **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents were $6,804 thousand, down from $7,575 thousand at the beginning of the period. - **Operating Activities**: Net cash used in operating activities was - $1,929 thousand in Q1 2026, compared to - $1,557 thousand in Q1 2025. This was primarily due to the net loss and changes in operating assets and liabilities. - **Investing Activities**: Net cash provided by investing activities was $1,000 thousand in Q1 2026, mainly from the maturity of a held-to-maturity investment. This contrasts with - $36 thousand used in investing activities in Q1 2025 for property and equipment purchases. - **Financing Activities**: Net cash provided by financing activities was $158 thousand in Q1 2026, primarily from $173 thousand in net proceeds from common stock issuance under the ATM Facility, partially offset by $15 thousand in note repayments. In Q1 2025, financing activities provided $1,941 thousand, including $1,066 thousand from common stock issuance and $889 thousand from warrant exercises. #### Future Outlook and Strategy SenesTech, Inc. expects its cash and cash equivalents, along with anticipated revenue, to fund current operations into the third quarter of 2027, assuming continued execution of its commercialization strategy and planned operating expenses. The company focuses on achieving sustainable revenue growth, progressing toward profitability through operational efficiency, manufacturing cost efficiencies, and sales channel optimization. Near-term priorities include scaling the Evolve product family, expanding e-commerce and retail/professional distribution, and strengthening its path to profitability, while also evaluating various financing alternatives. ### Related Stocks - [SNES.US](https://longbridge.com/en/quote/SNES.US.md) ## Related News & Research - [SenesTech to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 | SNES Stock News](https://longbridge.com/en/news/286963058.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Americold declares USD 0.23 per share Q2 2026 dividend](https://longbridge.com/en/news/287268362.md)